Mesentech Inc.
Mesentech is dedicated to developing innovative drugs that selectively target musculoskeletal tissues, utilizing novel chemistry to deliver payloads such as hormones and anti-cancer agents with high precision. Their technology aims to improve treatment efficacy while minimizing toxicity, with a focus on bone and muscle regeneration, especially for conditions like osteoporosis and muscular dystrophies.
Industries
Nr. of Employees
small (1-50)
Mesentech Inc.
2222 Health Sciences Mall, Vancouver, BC V6T1Z3, Canada
Products
Clinical-stage bone-targeted EP4 receptor agonist prodrug
A bone-targeted prodrug conjugate comprising a high-affinity bone-targeting moiety linked to an EP4 receptor agonist payload; designed to bind bone, minimize systemic exposure, and locally release active agonist over days.
Bone-selective oncology small-molecule conjugate (preclinical)
A small-molecule anti-cancer payload formulated as a bone-targeted conjugate designed to selectively distribute to bone tissue for localized oncology applications.
Clinical-stage bone-targeted EP4 receptor agonist prodrug
A bone-targeted prodrug conjugate comprising a high-affinity bone-targeting moiety linked to an EP4 receptor agonist payload; designed to bind bone, minimize systemic exposure, and locally release active agonist over days.
Bone-selective oncology small-molecule conjugate (preclinical)
A small-molecule anti-cancer payload formulated as a bone-targeted conjugate designed to selectively distribute to bone tissue for localized oncology applications.
Services
Partnership-based collaborations for translational evaluation, preclinical testing and IP licensing of bone-targeting conjugates; engagement with accelerators and external research platforms.
Partnership-based collaborations for translational evaluation, preclinical testing and IP licensing of bone-targeting conjugates; engagement with accelerators and external research platforms.
Expertise Areas
- Bone-targeted drug delivery
- Prodrug and linker chemistry
- Preclinical pharmacokinetics and biodistribution
- Bone regeneration and biomaterials
Key Technologies
- Bisphosphonate-mediated bone targeting
- Prodrug conjugation and linker chemistry
- Radiolabeling for pharmacokinetics and biodistribution
- Microcomputed tomography (microCT)
News & Updates
Mesentech announces the successful dosing of the first human participants in a randomized, double blind, placebo controlled clinical trial.
Rosy Hu, a member of the investment team at Morningside with a background in molecular biology from Harvard University, joins the company's board of directors.
Intellectual property covering new chemical entities for bone targeting conjugate drugs was granted by the Canadian Intellectual Property Office, with expiration in 2031.
A detailed publication on the design, synthesis, pharmacokinetics, and biodistribution of bone-targeting EP4 receptor agonist prodrugs for treating osteoporosis and other bone conditions.
Research showing that MES-1007 significantly improved bone density and geometry in severe osteogenesis imperfecta, demonstrating efficacy in a severe disease model.
A scientific article detailing the development of bone-targeting EP4 receptor agonist conjugate prodrugs, their stability, biodistribution, and potential for treating bone diseases.
Mesentech announces the successful dosing of the first human participants in a randomized, double blind, placebo controlled clinical trial.
Rosy Hu, a member of the investment team at Morningside with a background in molecular biology from Harvard University, joins the company's board of directors.
Intellectual property covering new chemical entities for bone targeting conjugate drugs was granted by the Canadian Intellectual Property Office, with expiration in 2031.
A detailed publication on the design, synthesis, pharmacokinetics, and biodistribution of bone-targeting EP4 receptor agonist prodrugs for treating osteoporosis and other bone conditions.
Research showing that MES-1007 significantly improved bone density and geometry in severe osteogenesis imperfecta, demonstrating efficacy in a severe disease model.
A scientific article detailing the development of bone-targeting EP4 receptor agonist conjugate prodrugs, their stability, biodistribution, and potential for treating bone diseases.